Chicago Capital LLC increased its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 8.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 65,800 shares of the medical equipment provider’s stock after buying an additional 5,137 shares during the quarter. ABIOMED comprises about 2.0% of Chicago Capital LLC’s holdings, making the stock its 18th biggest position. Chicago Capital LLC’s holdings in ABIOMED were worth $29,594,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of ABMD. MERIAN GLOBAL INVESTORS UK Ltd lifted its holdings in ABIOMED by 1,030.0% in the third quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock worth $287,325,000 after purchasing an additional 582,318 shares during the period. Renaissance Technologies LLC raised its position in ABIOMED by 35.0% in the second quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock worth $634,610,000 after acquiring an additional 401,800 shares in the last quarter. FMR LLC raised its position in ABIOMED by 34.2% in the second quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock worth $282,988,000 after acquiring an additional 176,394 shares in the last quarter. Carillon Tower Advisers Inc. raised its position in ABIOMED by 77.0% in the second quarter. Carillon Tower Advisers Inc. now owns 400,348 shares of the medical equipment provider’s stock worth $163,762,000 after acquiring an additional 174,198 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new stake in ABIOMED in the second quarter worth about $58,965,000. 87.14% of the stock is owned by institutional investors and hedge funds.
Shares of ABIOMED stock opened at $392.91 on Tuesday. ABIOMED, Inc. has a 52 week low of $186.72 and a 52 week high of $459.75. The stock has a market capitalization of $17.24 billion, a price-to-earnings ratio of 160.37, a price-to-earnings-growth ratio of 4.07 and a beta of 0.35.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.36. The firm had revenue of $181.78 million for the quarter, compared to the consensus estimate of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business’s revenue for the quarter was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.54 EPS. On average, equities analysts anticipate that ABIOMED, Inc. will post 3.49 EPS for the current year.
ABMD has been the topic of several research reports. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $457.00 price target on the stock in a research report on Tuesday, July 10th. BidaskClub cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. ValuEngine cut shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Morgan Stanley boosted their price target on shares of ABIOMED from $370.00 to $396.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Finally, BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price target on the stock in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $391.67.
In other ABIOMED news, VP Andrew J. Greenfield sold 4,440 shares of the business’s stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total transaction of $1,753,800.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the sale, the vice president now owns 48,954 shares in the company, valued at approximately $21,172,605. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Shares Bought by Chicago Capital LLC” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/11/06/abiomed-inc-abmd-shares-bought-by-chicago-capital-llc.html.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Read More: Insider Trading
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.